JPMorgan Is The Rally Over?
JPMorgan Chase (NYSE:JPM) share price is up 29% over the…
Sell
32
RPRX Quote, Financials, Valuation and Earnings
Last price:
$32.61
Seasonality move
:
-5.07%
Day range:
$32.09 - $32.67
52-week range:
$24.05 - $34.20
Dividend yield:
2.61%
P/E ratio:
18.08x
P/S ratio:
8.56x
P/B ratio:
2.03x
Volume:
2.5M
Avg. volume:
4.8M
1-year change:
18.07%
Market cap:
$14.1B
Revenue:
$2.3B
EPS (TTM):
$1.80
Analysts' Opinion
-
Consensus RatingRoyalty Pharma PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $40.04, Royalty Pharma PLC has an estimated upside of 22.81% from its current price of $32.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.14 representing 100% downside risk from its current price of $32.60.
Fair Value
-
According to the consensus of 6 analysts, Royalty Pharma PLC has 22.81% upside to fair value with a price target of $40.04 per share.
RPRX vs. S&P 500
-
Over the past 5 trading days, Royalty Pharma PLC has overperformed the S&P 500 by 6.05% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Royalty Pharma PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Royalty Pharma PLC revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Royalty Pharma PLC reported revenues of $593.6M.
Earnings Growth
-
Royalty Pharma PLC earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Royalty Pharma PLC reported earnings per share of $0.35.
Enterprise value:
23.4B
EV / Invested capital:
--
Price / LTM sales:
8.56x
EV / EBIT:
15.01x
EV / Revenue:
10.32x
PEG ratio (5yr expected):
0.02x
EV / Free cash flow:
8.44x
Price / Operating cash flow:
6.99x
Enterprise value / EBITDA:
15.01x
Gross Profit (TTM):
--
Return On Assets:
4.97%
Net Income Margin (TTM):
37.95%
Return On Equity:
8.54%
Return On Invested Capital:
5.03%
Operating Margin:
60.9%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.4B | $2.3B | $596.1M | $593.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $922.9M | $1.5B | $1.3B | $612.9M | $361.5M | |
| EBITDA | $423.7M | $1.9B | $1.6B | $764.8M | $400.1M | |
| Diluted EPS | -$0.33 | $2.52 | $1.80 | $1.10 | $0.35 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.7B | $2.9B | $2.6B | $1.3B | $1.8B | |
| Total Assets | $16B | $17.5B | $16.8B | $16.4B | $18.2B | |
| Current Liabilities | $307.9M | $171.3M | $1.2B | $161.4M | $1.3B | |
| Total Liabilities | $6.1B | $7.3B | $7.3B | $6.3B | $7.9B | |
| Total Equity | $9.9B | $10.2B | $9.5B | $10.1B | $10.3B | |
| Total Debt | $5.8B | $7.1B | $7.1B | $6.1B | $7.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.1B | $3B | $2.8B | $772.6M | $742.5M | |
| Cash From Investing | -$1B | -$2.1B | -$2.7B | -$1B | -$505.6M | |
| Cash From Financing | -$944.9M | -$2.1B | $361.1M | -$231.9M | -$258M | |
| Free Cash Flow | $2.1B | $3B | $2.8B | $772.6M | $742.5M | |
RPRX
Sector
Market Cap
$14.1B
$35M
Price % of 52-Week High
95.32%
42.2%
Dividend Yield
2.61%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
18.07%
-41.61%
Beta (5-Year)
--
0.742
Dividend yield:
2.61%
Annualized payout:
$0.84
Payout ratio:
43.83%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$31.98
200-day SMA
Buy
Level
$28.79
Bollinger Bands (100)
Buy
Level
26.92 - 33.22
Chaikin Money Flow
Buy
Level
17.2M
20-day SMA
Buy
Level
$31.96
Relative Strength Index (RSI14)
Buy
Level
54.59
ADX Line
Sell
Level
21.14
Williams %R
Sell
Level
-2.1631
50-day SMA
Buy
Level
$32.55
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
90.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.527)
Sell
CA Score
(Annual)
Level (-0.517)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-1.1729)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Stock Forecast FAQ
In the current month, RPRX has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RPRX average analyst price target in the past 3 months is $40.04.
-
Where Will Royalty Pharma PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Royalty Pharma PLC share price will rise to $40.04 per share over the next 12 months.
-
What Do Analysts Say About Royalty Pharma PLC?
Analysts are divided on their view about Royalty Pharma PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Royalty Pharma PLC is a Sell and believe this share price will drop from its current level to $30.14.
-
What Is Royalty Pharma PLC's Price Target?
The price target for Royalty Pharma PLC over the next 1-year time period is forecast to be $40.04 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RPRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Royalty Pharma PLC is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RPRX?
You can purchase shares of Royalty Pharma PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Royalty Pharma PLC shares.
-
What Is The Royalty Pharma PLC Share Price Today?
Royalty Pharma PLC was last trading at $32.61 per share. This represents the most recent stock quote for Royalty Pharma PLC. Yesterday, Royalty Pharma PLC closed at $32.60 per share.
-
How To Buy Royalty Pharma PLC Stock Online?
In order to purchase Royalty Pharma PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BlackRock a Buy, Sell or Hold
With a large suite of ETF offerings as well as…
Is Uber Stock a Buy, Sell or Hold?
Uber (NYSE:UBER) has been through quite a ride over the…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 18
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 18
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 18
Global Payments [GPN] is down 17.44% over the past day.
